Business context and reporting period
Entity discrepancy: The supplied filing is Global Medical REIT Inc.’s Form 10-Q, not a filing for Chiron Real Estate Inc. It covers the quarter ended March 31, 2021; the financial statements are unaudited. Global Medical REIT acquires purpose-built healthcare facilities and leases them primarily to healthcare systems and physician groups.
At quarter-end, the portfolio comprised 90 facilities and approximately 3.8 million leasable square feet. The company completed four acquisitions during the quarter for an aggregate purchase price of approximately $42.8 million.
Key financial results
Amounts below are in millions of dollars except per-share data and where noted.
| Metric | Q1 2021 | Q1 2020 / prior date |
|---|---|---|
| Total revenue | $27.35 | $21.65 |
| Net income | $3.32 | $2.82 |
| Net income attributable to common stockholders | $1.76 | $1.26 |
| Common-stockholder earnings per share, diluted | $0.03 | $0.03 |
| FFO per share and unit | $0.23 | $0.19 |
| AFFO per share and unit | $0.24 | $0.20 |
| Net cash provided by operating activities | $15.29 | $12.26 |
| Cash and restricted cash, quarter-end | $11.40 | $16.88 at March 31, 2020 |
| Total debt, net of issuance costs | $485.03 | $586.58 at December 31, 2020 |
| Total equity, including noncontrolling interests | $595.82 | $457.76 at December 31, 2020 |
Rental revenue rose 26.9% year over year, primarily reflecting acquisitions completed after March 31, 2020 and a full quarter of revenue from properties acquired in Q1 2020. GAAP net income margin was approximately 12.2%, versus 13.0% in Q1 2020. Net income increased, while common-stockholder EPS remained $0.03 as weighted-average common shares increased to 52.7 million from 44.2 million.
Operating expenses increased to $24.03 million from $18.83 million. General and administrative expense rose to $4.38 million, partly because costs previously borne by the external adviser shifted to the company after management internalization; stock-based compensation also increased. Depreciation and amortization rose with the larger property portfolio. Interest expense increased to $5.04 million from $4.38 million.
Cash flows were $15.29 million provided by operations, $43.57 million used in investing, and $28.93 million provided by financing. Financing included $144.31 million in net common-equity proceeds and a net $101.70 million repayment on the credit facility. The common dividend was $0.205 per share, compared with $0.20 a year earlier; AFFO per share and unit was $0.24.
Changes, outlook, and risks
- Capital and debt: The company issued 8.625 million shares in a public offering at $13.30 per share and issued 2.709 million shares through its at-the-market program. Credit-facility borrowings fell from $525.2 million gross at year-end 2020 to $423.5 million at March 31, 2021. The quarter-end weighted-average interest rate on debt was 3.66%, compared with 3.17% at December 31, 2020.
- Subsequent financing: On May 3, 2021, the company amended and restated its credit facility, increasing capacity from $600 million to $750 million, converting it to unsecured debt, and extending maturities to 2025 for the revolver and 2026 for the term loan. Management reported covenant compliance as of May 3. New forward-starting swaps were entered into on May 4.
- Acquisition activity: After quarter-end, the company reported five additional acquisitions for $58.2 million and three properties under contract for approximately $32.3 million; those pending transactions remained subject to due diligence.
- Management outlook: No quantified earnings or acquisition guidance is provided. Management said COVID-19 had not materially affected the business through Q1 2021, but a resurgence could impair tenant rent payments, lending, or access to equity capital. Management also cited healthcare demand and outpatient-care trends as potential supports, while warning of competition for acquisitions and pressure on tenants from healthcare reimbursement changes.
- Interest-rate and other risks: The company had $73.5 million of unhedged floating-rate borrowings at March 31; a 100-basis-point LIBOR increase was estimated to reduce annual cash flow by approximately $0.7 million, assuming debt remained unchanged. LIBOR transition, tenant defaults or non-renewals, rent collection, debt covenants, refinancing, climate-related property impacts, and REIT qualification are among the disclosed risks.
- Commitments and contingencies: Planned or potential capital-improvement obligations were approximately $29.5 million, with up to $18.9 million potentially due in the next 12 months. The filing reports no material pending litigation or known material environmental liability.
Important facts for investors to verify
- Confirm the intended issuer: this text identifies Global Medical REIT Inc., not Chiron Real Estate Inc.
- Review acquisition-level rent, tenant credit quality, lease terms, and the company’s ability to collect rent, including the disclosed tenant receivable reserve.
- Assess dilution from equity issuance against growth in FFO and AFFO, and compare recurring cash generation with common and preferred dividends.
- Check debt availability, maturities, covenant headroom, interest-rate exposure, and the effects of the May 2021 unsecured refinancing and swaps.
- Track the $29.5 million improvement commitments, subsequent acquisitions, and properties still under contract, including their funding and expected returns.